Figure 2

Kaplan-Meier Disease-free survival curves. A: Disease-free survival comparison among histological types. Endometrioid vs. Mucinous (Log-Rank p = 0.016; HR = 5.18; CI95% = 1.36-19.74); Endometrioid vs. Serous (Log-Rank p = 0.048; HR = 3.29; CI95% = 1.01-10.70); Serous vs. Mucinous (Log-Rank p = 0.072; HR = 1.19; CI96% = 0.37-3.82). B: Disease-free survival comparison among FIGO stages. I vs. II (Log-Rank p = 0.071; HR = 1.31; CI95% = 0.38-7.87); I vs. III (Log-Rank p = 0.109; HR = 2.38; CI95% = 0.82-6.88); I vs. IV (Log-Rank p = 0.005; HR = 17.09; CI95% = 2.31-126.07); II vs. III (Log-Rank p = 0.408; HR = 1.73; CI95% = 0.47-6.37); II vs. IV (Log-Rank p = 0.136; HR = 3.66; CI95% = 0.66-20.18); III vs. IV (Log-Rank p = 0.157; HR = 3.64; CI95% = 0.75-17.75). C: Disease-free survival comparison among groups of age at diagnosis. 40 years old or less vs. 41 to 60 years old (Log-Rank p = 0.026; HR = 3.75; CI95% = 1.17-11.91); 40 years old or less × above 60 years old (Log-Rank p = 0.021; HR = 4.72; CI95% = 1.26-17.72); 41 to 60 years old × above 60 years old (Log-Rank p = 0.406; HR = 1.42; CI95% = 0.62-3.28). D: Disease-free survival comparison among adjuvant treatment regimens. Platinum only × Platinum-Paclitaxel (Log-Rank p = 0.488; HR = 1.72; CI95% = 0.37-7.95); Platinum only × Platinum-Ciclophosphamide (Log-Rank p = 0.042; HR = 8.95; CI95% = 1.08-73.95); Platinum-Paclitaxel × Platinum-Ciclophosphamide (Log-Rank p = 0.121; HR = 2.65; CI95% = 0.77-9.05).